Clinicopathological Evaluation and Prognostic Analysis in Breast Cancer Patients with Brain Metastasis


Background: Brain metastases are diagnosed in 5% - 15% of patients with breast cancer. Clinical management of brain metastases appears to be crucial in improving the prognosis of patients with breast cancer that has metastasized to the brain. However, few studies have investigated whether treatment of metastatic brain tumors would lead to improved prognosis. Methods: A total of 41 breast cancer patients whose tumors metastasized to the brain and who were diagnosed and treated at our hospital were enrolled. This study was conducted to determine the characteristics of brain metastases and to identify the factors that may affect the treatment and prognosis of patients with brain metastases. Results: There were more patients with HER2 and triple negative subtypes than of the luminal subtype. The median time from the initiation of breast cancer treatment to the onset of brain metastasis was 31 months (range, 7 - 134 months). Significantly greater disease-specific survival (DSS) was observed in patients who had a performance status of 0 - 2 at the time of diagnosis of metastatic brain tumors than those with a performance status of 3 - 4 (p = 0.04). DSS was also significantly greater in patients who underwent surgery to remove brain metastases and in patients treated with systemic therapy (p = 0.0007 and 0.0001, respectively). Conclusions: It may be possible to improve the prognosis of patients with brain metastases if lesions are detected early enough when the patients’ performance status is still good. In order for these findings to be definitive, however, results of future prospective studies are eagerly awaited.

Share and Cite:

Minatani, N. , Tanino, H. , Kosaka, Y. , Kikuchi, M. , Nishimiya, H. , Waraya, M. , Katoh, H. , Enomoto, T. , Sengoku, N. and Watanabe, M. (2015) Clinicopathological Evaluation and Prognostic Analysis in Breast Cancer Patients with Brain Metastasis. Journal of Cancer Therapy, 6, 727-734. doi: 10.4236/jct.2015.68079.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Siegel, R., Ward, E., Brawley, O. and Jemal, A. (2011) Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths. CA: A Cancer Journal for Clinicians, 61, 212-236.
[2] DiStefano, A., Yong Yap, Y., Hortobagyi, G.N. and Blumenschein, G.R. (1979) The Natural History of Breast Cancer Patients with Brain Metastases. Cancer, 44, 1913-1918.<1913::AID-CNCR2820440554>3.0.CO;2-D
[3] Marko, N.F., Xu, Z., Gao, T., Kattan, M.W. and Weil, R.J. (2011) Predicting Survival in Women with Breast Cancer and Brain Metastasis: A Nomogram Outperforms Current Survival Prediction Models. Cancer, 118, 3749-3757.
[4] Tsukada, Y., Fouad, A., Pickren, J.W. and Lane, W.W. (1983) Central Nervous System Metastasis from Breast Carcinoma. Autopsy Study. Cancer, 52, 2346-2354.<2349::AID-CNCR2820521231>3.0.CO;2-B
[5] Kaplan, M.A., Ertugrul, H. and Firat, U. (2014) Brain Metastases in HER2-Positive Metastatic Breast Cancer Patients Who Received Chemotherapy with or without Trastuzumab. Breast Cancer.
[6] Lin, N.U., Bellon, J.R. and Winer, E.P. (2004) CNS Metastases in Breast Cancer. Journal of Clinical Oncology, 22, 3608-3617.
[7] Tarhan, M.O., Demir, L., Somali, I., Yigit, S., Erten, C., Alacacioglu, A., et al. (2013) The Clinicopathological Evaluation of the Breast Cancer Patients with Brain Metastases: Predictors of Survival. Clinical & Experimental Metastasis, 30, 201-213.
[8] Graesslin, O., Abdulkarim, B.S., Coutant, C., Huguet, F., Gabos, Z., Hsu, L., Marpeau, O., et al. (2010) Nomogram to Predict Subsequent Brain Metastasis in Patients with Metastatic Breast Cancer. Journal of Clinical Oncology, 28, 2032-2037.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.